Novartis profits dip as generic rival challenges cancer drug

GENEVA (AP) — Swiss pharmaceuticals maker Novartis says net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines.